Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer

This Review concludes that based on two small RCTs, there is not enough evidence to comment on the safety and effectiveness of LHRH agonists in the treatment of platinum-refractory and platinum-resistant (relapsed) EOC. Overall, the quality of evidence for all outcomes (including OS, PFS, QoL and adverse events) is very low.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news